Etiology and clinical course of febrile neutropenia in children with cancer

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 9, 2009, Pages 623-629

  Hakim, Hana ^a   Flynn, Patricia M ^a,b   Knapp, Katherine M ^a,b   Srivastava, Deo Kumar ^a   Gaur, Aditya H ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Children; Etiology; Fever; Microbiology; Neutropenia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD CULTURE; BLOOD SAMPLING; CANCER CENTER; CANCER PATIENT; CHILD; CONTROLLED STUDY; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS; SCHOOL CHILD; STREPTOCOCCUS; VIRUS VIRULENCE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTEREMIA; CANCER CARE FACILITIES; CHILD; CHILD, PRESCHOOL; FEVER; FEVER OF UNKNOWN ORIGIN; HOSPITALS, PEDIATRIC; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; LENGTH OF STAY; MYCOSES; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; TENNESSEE; VIRUS DISEASES;

EID: 70349119094     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b1edc6     Document Type: Article

References (41)

1. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(suppl 4):S240-S245.
2. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
3. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490-494.
4. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36: 1103-1110. (Pubitemid 36553108)
5. Yadegarynia D, Tarrand J, Raad I, et al. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 2003;37:1144-1145.
6. Koll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. Clin Infect Dis. 1993;17(suppl 2):S322-S328.
7. Gaur AH, Giannini MA, Flynn PM, et al. Optimizing blood culture practices in pediatric immunocompromised patients: evaluation of media types and blood culture volume. Pediatr Infect Dis J. 2003;22:545-552.
8. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
9. Ariffin H, Navaratnam P, Lin HP. Surveillance study of bacteraemic episodes in febrile neutropenic children. Int J Clin Pract. 2002;56:237-240.
10. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapyinduced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45: 1296-1304.
11. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18:72-77.
12. Mullen CA, Buchanan GR. Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol. 1990;8:1998-2004.
13. Lawson RD, Gentry LO, Bodey GP, et al. A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci. 1984;287:16-23.
14. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415-3421.
15. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(suppl 1):S51-S59.
16. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18: 3038-3051.
17. Kamana M, Escalante C,Mullen CA, et al. Bacterial infections in low-risk, febrile neutropenic patients. Cancer. 2005;104:422-426.
18. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580-588.
19. Velasco E, Byington R, Martins CS, et al. Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect. 2004;10:542-549.
20. Paul M, Gafter-Gvili A, Leibovici L, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Isr Med Assoc J. 2007;9:424-429.
21. Greenberg D, Moser A, Yagupsky P, et al. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents. 2005;25:469-473.
22. Gaytan-Martinez J, Mateos-Garcia E, Sanchez-Cortes E, et al. Microbiological findings in febrile neutropenia. Arch Med Res. 2000;31:388-392.
23. Kanafani ZA, Dakdouki GK, El-Chammas KI, et al. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade. Int J Infect Dis. 2007;11:450-453.
24. Reilly AF, Lange BJ. Infections with viridans group streptococci in children with cancer. Pediatr Blood Cancer. 2007;49:774-780.
25. Okamoto Y, Ribeiro RC, Srivastava DK, et al. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2003;25:696-703.
26. Paganini H, Staffolani V, Zubizarreta P, et al. Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors. Eur J Cancer. 2003;39:1284-1289.
27. Shenep JL. Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents. 2000;14: 129-135.
28. Rossetti F, Cesaro S, Putti MC, et al. High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. Pediatr Hematol Oncol. 1995;12:387-392.
29. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113: 376-382.
30. Santolaya ME, Alvarez AM, Aviles CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004;22:3784-3789.
31. Klaassen RJ, Allen U, Doyle JJ. Randomized placebocontrolled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol Oncol. 2000;22:405-411.
32. Innes HE, Smith DB, O'Reilly SM, et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer. 2003;89:43-49.
33. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24: 4129-4134.
34. Shenep JL, Flynn PM, Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis. 2001;32:36-43.
35. Stabell N, Nordal E, Stensvold E, et al. Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis. 2008;40:301-307.
36. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743-746.
37. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950-952.
38. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425-429.
39. Santolaya ME, Alvarez AM, Aviles CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007;26:794-798.
40. Klaassen RJ, Goodman TR, Pham B, et al. ''Low-risk'' prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019.
41. Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006;28:665-670.